Acceleron Pharma

Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases. Its pioneering research platform leverages the powerful biology behind the body’s ability to rebuild and repair its own cells and tissues. This approach to drug discovery has generated four therapeutic candidates that are currently in clinical trials.


Company Growth (employees)
Type
Public
HQ
Cambridge, US
Founded
2004
Size (employees)
121 (est)+19%
Acceleron Pharma was founded in 2004 and is headquartered in Cambridge, US

Key People at Acceleron Pharma

Habib Dable

Habib Dable

President and Chief Executive Officer
Kevin McLaughlin

Kevin McLaughlin

Chief Financial Officer
Steven Ertel

Steven Ertel

Chief Operating Officer
Matthew Sherman

Matthew Sherman

Chief Medical Officer
Ravi Kumar

Ravi Kumar

Chief Scientific Officer
John Quisel

John Quisel

SVP, Business Development and General Councel
Christopher Rovaldi

Christopher Rovaldi

VP, Program Management

Acceleron Pharma Office Locations

Acceleron Pharma has office in Cambridge
Cambridge, US

Acceleron Pharma Metrics

Acceleron Pharma Summary

Market capitalization

$1.1 b

Closing share price

$28
Acceleron Pharma's current market capitalization is $1.1 b.

Acceleron Pharma Financials

Acceleron Pharma's revenue is $57.2 m in FY, 2013 which is a 291.1% increase from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

$57.2 m$14.6 m$18.1 m$27.8 m

Revenue growth, %

(74.4%)23.7%53.5%

EBIT

$7 m($55.5 m)($60.9 m)

Net Income

($21.9 m)($51.3 m)($63.9 m)($57 m)

Operating cash flow

$73.6 m$63.3 m($148.7 m)

Acceleron Pharma Operating Metrics

FY, 2015FY, 2016

Ongoing Phase III Programs

22

Acceleron Pharma Market Value History

Acceleron Pharma Online Presence

Acceleron Pharma Company Life

You may also be interested in